



Report on Utilization of IPO Proceeds  
For the Month of January 2019

Name of the Company: The ACME Laboratories Ltd.  
Amount (BDT) of capital raised through IPO: BDT 4,096,000,000 (Received amount BDT 4,095,015,601.38 net of foreign currency conversion loss)  
Date of Close of Subscription: 21 April 2016  
Proceeds Receiving Date: 11 April 2016 to 21 April 2016  
Last Date of Full Utilization of IPO Fund as per 40th AGM/42nd AGM : As stated in time line columns

S.L	Purpose mentioned in the 40th AGM/42nd AGM	Time Line As per 40th AGM	As per 42nd AGM	Cost Breakdown	Amount as per			Status of Utilization			Un utilized %	Remarks
					40th AGM	42nd AGM	Amount	Utilized %	Total un utilized amount			
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e., 2018	Within June 2019	Civil Construction	334,934,878	334,934,878	-	334,934,878	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Phinaki and Company, Chartered Accountants
				Machinery & Equipment	598,600,000	933,900,000	890,148,697	933,900,000	100.00%	-	0.00%	
				Utility	339,600,000	353,700,000	14,100,000	353,700,000	100.00%	-	0.00%	
				Warehouse	39,500,000	21,986,000	1,302,156	21,986,000	100.00%	-	0.00%	
				Vehicle	5,000,000	5,000,000	-	5,000,000	100.00%	-	0.00%	
				Contingencies	26,300,000	1,200,000	-	1,200,000	100.00%	-	0.00%	
				<b>Sub Total</b>	<b>1,358,000,000</b>	<b>1,660,591,186</b>	<b>78,535,147</b>	<b>1,660,591,186</b>	<b>100.00%</b>	<b>0.00%</b>		
2	Penicillin Project	Within the month of March 2018	Within June 2019	Civil Construction	116,000,000	142,922,303	-	142,922,303	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Phinaki and Company, Chartered Accountants
				Machinery & Equipment	132,299,520	79,768,602	829,144	79,768,602	100.00%	-	0.00%	
				Utility	117,154,000	146,345,797	117,154,000	146,345,797	100.00%	-	0.00%	
				Warehouse	20,582,700	21,641,545	3,406,448	21,641,545	100.00%	-	0.00%	
				Vehicle	3,000,000	2,901,503	-	2,901,503	100.00%	-	0.00%	
				Contingencies	5,963,780	1,420,250	-	1,420,250	100.00%	-	0.00%	
				<b>Sub Total</b>	<b>400,000,000</b>	<b>400,000,000</b>	<b>126,366,352</b>	<b>400,000,000</b>	<b>100.00%</b>	<b>0.00%</b>		
3	Active Pharmaceuticals Ingredients (API)	Within 2-3 years after getting permission from the Ministry of Industries	Within June 2022	Civil Construction	347,860,000	355,637,304	-	355,637,304	42.54%	204,350,280	57.46%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Phinaki and Company, Chartered Accountants
				Machinery & Equipment	493,000,000	250,495,241	-	250,495,241	100.00%	-	0.00%	
				Utility	409,400,000	-	-	-	-	-	-	
				Warehouse	38,500,000	-	-	-	-	-	-	
				Vehicle	3,000,000	-	-	-	-	-	-	
				Contingency fee	23,635,200	-	-	-	-	-	-	
				<b>Sub Total</b>	<b>1,355,228,292</b>	<b>606,132,545</b>	<b>151,287,024</b>	<b>151,287,024</b>	<b>24.96%</b>	<b>454,845,521</b>	<b>75.04%</b>	
4	Repayment of Bank Borrowing at 40th AGM	N/A	N/A		1,360,000,000	1,360,000,000	-	1,360,000,000	100.00%	-	0.00%	
5	IPO Expenses	N/A	N/A		68,291,870	68,291,870	-	68,291,870	100.00%	-	0.00%	
<b>Total</b>					<b>4,541,520,162</b>	<b>4,095,015,601</b>	<b>204,901,499</b>	<b>3,640,170,080</b>	<b>88.89%</b>	<b>454,845,521</b>	<b>11.11%</b>	

Percentage (Interest on FDR to be matured on 27 March 2019 & 06 April 2019)  
Interest on IPO Proceeds in BDT (from FDR & SND)  
Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Foyza Haque, FCA  
Independent Director & Chairman of the Audit Committee

Mizanur Rahman Sinha  
Managing Director

Nagina Afzal Sinha  
Chairman

Pinaki & Company  
Chartered Accountants